Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;39(6):1311-1324.
doi: 10.1038/s41375-025-02620-8. Epub 2025 Apr 19.

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management

Douglas Tremblay  1 , Robert P Hasserjian  2 , Raajit K Rampal  3
Affiliations
Review

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management

Douglas Tremblay et al. Leukemia. 2025 Jun.

Abstract

Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes are a rare group of biologically and clinically connected hematologic malignancies that includes chronic myelomonocytic leukemia (CMML), the most common subtype, as well as atypical chronic myeloid leukemia, MDS/MPN with SF3B1 and thrombocytosis, and MDS/MPN, not otherwise specified. Given their rarity and overlapping clinical features, accurate diagnosis and risk stratification presents a significant challenge. Therapeutic approaches are largely borrowed from either MDS or MPN and the only curative option for appropriate patients is allogeneic stem cell transplantation. Recent advances have started to uncover the pathobiologic basis for these diseases, leading to novel clinical trials for MDS/MPN overlap syndromes, in particular CMML. This review is a practical guide for the diagnosis and management of MDS/MPN overlap syndromes and presents novel therapeutics being specifically designed for these diseases to improve their historically poor outcomes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DT receives contracted research funding paid to his institution from Sobi, Sumitomo, Cogent Biosciences and Gilead and consulting fees from Sobi, AbbVie, Pharmaessentia, Sierra Oncology, GSK and Cogent Biosciences. RKR receives contracted research funding pain to his institution from Constellation pharmaceuticals, Ryvu, Sumitomo, Zentalis and Stemline Therapeutics and consulting fees from Incyte Corporation, Celgene/BMS, Blueprint, Abbvie, CTI, Stemline, Galecto, Pharmaessentia, Jubilant, Constellation/Morphosys, Sierra Oncology/GSK, Protagonist, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, Karyopharm. RPH declares no relevant conflicts of interest.

References

    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. - PubMed - PMC - DOI
    1. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours, 5th edn, vol. 11. Lyon (France): International Agency for Research on Cancer; 2024.
    1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302. - PubMed - DOI
    1. Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adema V, Fuhrmann I, et al. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood. 2020;136:1851–62. - PubMed - PMC - DOI
    1. Guru Murthy GS, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leuk Lymphoma. 2017;58:1648–54. - PubMed - DOI

MeSH terms

LinkOut - more resources